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Background: Missing data are often an issue in electronic medical records (EMRs) research. 
However, there are many ways that people deal with missing data in drug safety studies.
Aim: To compare the risk estimates resulting from different strategies for the handling of miss-
ing data in the study of venous thromboembolism (VTE) risk associated with antiosteoporotic 
medications (AOM).
Methods: New users of AOM (alendronic acid, other bisphosphonates, strontium ranelate, selec-
tive estrogen receptor modulators, teriparatide, or denosumab) aged ≥50 years during 1998–2014 
were identified in two Spanish (the Base de datos para la Investigación Farmacoepidemiológica 
en Atención Primaria [BIFAP] and EpiChron cohort) and one UK (Clinical Practice Research 
Datalink [CPRD]) EMR. Hazard ratios (HRs) according to AOM (with alendronic acid as refer-
ence) were calculated adjusting for VTE risk factors, body mass index (that was missing in 61% 
of patients included in the three databases), and smoking (that was missing in 23% of patients) in 
the year of AOM therapy initiation. HRs and standard errors obtained using cross-sectional mul-
tiple imputation (MI) (reference method) were compared to complete case (CC) analysis – using 
only patients with complete data – and longitudinal MI – adding to the cross-sectional MI model 
the body mass index/smoking values as recorded in the year before and after therapy initiation.
Results: Overall, 422/95,057 (0.4%), 19/12,688 (0.1%), and 2,051/161,202 (1.3%) VTE cases/
participants were seen in BIFAP, EpiChron, and CPRD, respectively. HRs moved from 100.00% 
underestimation to 40.31% overestimation in CC compared with cross-sectional MI, while 
longitudinal MI methods provided similar risk estimates compared with cross-sectional MI. 
Precision for HR improved in cross-sectional MI versus CC by up to 160.28%, while longitu-
dinal MI improved precision (compared with cross-sectional) only minimally (up to 0.80%).
Conclusion: CC may substantially affect relative risk estimation in EMR-based drug safety 
studies, since missing data are not often completely at random. Little improvement was seen in 
these data in terms of power with the inclusion of longitudinal MI compared with cross-sectional 
MI. The strategy for handling missing data in drug safety studies can have a large impact on 
both risk estimates and precision.
Keywords: missing data, electronic medical records, pharmacoepidemiology, multiple imputa-
tion, complete case analysis, longitudinal data
Background
Electronic medical record (EMR) databases are a commonly used data source for drug 
safety research.1 They provide exceptional value for the study of suspected unwanted 
effects not tested in randomized clinical trials (RCT) and for the high proportion of 
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drug users in the community who are deemed not eligible for 
participation in RCTs.2 Notwithstanding these benefits, the 
lack of full records on key variables (ie, missing data) can 
pose a real challenge to conducting EMR research.
Missing data are a well-recognized issue that can compro-
mise statistical power, as “complete case (CC)” analyses will 
automatically exclude subjects with missing information for 
any of the variables included in multivariable models. More 
importantly, if data are missing at random (MAR), but not 
completely at random, analyses based on CCs may be biased,3 
and researchers may not be aware of this.
Likewise, including a “missing data indicator” variable 
in the analysis is a widely used strategy likely to introduce 
bias.4,5 Such biases can be overcome by using methods 
such as multiple imputation (MI), which allow individuals 
with incomplete data to be included in analyses.3 However, 
MI methods are still seldom used in EMR-based post- 
authorization safety studies.6
In this study, our aim was to compare the risk estimates 
observed when applying CC analysis versus MI and give the 
reader an intuitive understanding and practical overview of the 
potential issues and limitations of using CC and longitudinal 
MI by taking the cross-sectional MI as the reference. As a 
part of a cohort study on the risk of venous thromboembolism 
(VTE) associated with the use of different antiosteoporotic 
medications (AOM),7 we explored the issues of missing data 
and compared different methods using data from three different 
EMR databases from Spain and the UK. Our secondary aim 
was to describe a step-by-step approach for setting up and con-
ducting MIs in drug safety studies using EMR data and to list 
practical challenges faced during the MI process. We followed 
the guidelines for this process provided by previous authors.3,5,8
Methods
Sources of data
We obtained data from primary care deidentified computer-
ized medical records from two different EMR databases in 
Spain (the Base de datos para la Investigación Farmacoepide-
miológica en Atención Primaria [BIFAP]9 and the EpiChron 
Cohort10) and one from the UK (Clinical Practice Research 
Datalink [CPRD]).11 These databases include information 
on patient age, sex, life-style factors, clinical events, drug 
prescriptions, specialist referrals, and laboratory test results 
for millions of primary care patients.
Study population and exposure cohorts
The study population was formed by all patients aged ≥50 
years with at least 1 year of available recorded data and a 
prescription or dispensation of AOM (date for therapy initia-
tion) during each database study period, that is, 2000–2014 
(CPRD), 2001–2013 (BIFAP), and 2010–2011 (EpiChron). 
Patients with a prescription or dispensation of AOM recorded 
during the year before therapy initiation were considered as 
prevalent users and thus excluded from the study.
Six exposure cohorts were identified according to the 
first AOM prescribed as follows: 1) alendronic acid (Ana-
tomical Therapeutic Chemical classifications M05BA04 
and M05BB03); 2) other oral bisphosphonates (etidronic 
acid [M05BA01], ibandronic acid [M05BA06], risedronic 
acid [M05BA07], clodronic acid [M05BA02], and tiludronic 
acid [M05BA05] – the two latter available only in Spain-); 
3) selective estrogen receptor modulators (bazedoxifene 
[G03XC01] and raloxifene [G03XC02]); 4) strontium ranelate 
(M05BX03); 5) denosumab (M05BX04); and 6) teriparatide 
(H05AA02). We considered treatment episodes of prescribing 
including prescription durations with <180 days gap.
Case ascertainment and follow-up
Participants from exposure cohorts were followed from the 
day after therapy initiation to the earliest of the following: a 
record of treated VTE diagnosis (cases), end of first AOM 
treatment episode (end of supply of the last prescription before 
a gap of 180 days), switching to an alternative cohort exposure, 
lost to follow-up, death, or end of study period. A list of Read 
and International Classification of Primary Care (ICPC) codes 
for identification of VTE diagnosis recording in CPRD and 
BIFAP/EpiChron, respectively, is reported elsewhere.7 Read 
codes were developed by Dr James Read, and are standard 
clinical terminology in UK primary care practice.
Confounders
Factors associated with VTE risk according to The National 
Institute for Health and Care Excellence guidelines12 were 
collected as potential confounders: 1) history of VTE, cancer, 
peripheral arterial disease, vein insufficiency as recorded 
at any time before the date of therapy initiation; 2) use of 
hormone replacement therapy (HRT) during the year before 
therapy initiation; 3) fractures recorded in the 2 months before 
therapy initiation (used as a proxy for bed-bound patients 
in the target population of incident AOM drug users); and 
4) body mass index (BMI) in kg/m2 (as a continuous vari-
able) and smoking status, as recorded in the year of therapy 
initiation (the closest value to January 1 in case of repeated 
records in that same year). Smoking status was assessed as 
a binary variable (current smoker yes/no) where nonsmokers 
included both ex and never smokers. Patients with recorded 
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status of exclusively “never smoker” at the age of ≥40 years 
were considered as nonsmokers even in the presence of miss-
ing data in the year of therapy initiation. This is because it is 
unlikely that many people aged >40 years will take up smok-
ing later in life.13 Also, the Charlson comorbidity index was 
calculated14 (CPRD) or an equivalent list of comorbidities 
included in the latter index (EpiChron/BIFAP). Alcohol abuse 
(“yes/no” as ICPC symptom/complaint recorded by the pri-
mary care practitioner in EpiChron/BIFAP) and use of other 
AOM (ie, parathyroid hormone, calcitonin, and elcatonin), 
calcium–vitamin D supplements, systemic corticosteroids, 
heparins, and oral anticoagulant drugs were also included 
in the analyses.
Statistical analyses
Cox regression models adjusted for all confounders listed 
above were applied in each EMR database separately (ie, 
substantive model) to quantify the risk of VTE (hazard ratios 
[HRs] and 95% confidence intervals [CIs]) associated with 
the different AOM compared with alendronic acid. Stata 
program by StataCorp LP was used for statistical analysis. 
Regarding the MI of missing data, we followed a step-by-
step strategy based on the guidance provided by Sterne et al,3 
White et al,8 and Pedersen et al5 as described below:
1. Reflecting on the nature of missing data
In the proposed scenario, two variables had missing informa-
tion in the year of therapy initiation: smoking status and BMI. 
Most software that implements MI assumes that missing 
data are MAR, meaning, given the observed data, data are 
missing independent of unobserved data.15 The assumption of 
the existence of such variables is relatively easy to accept in 
EMR-based research, as for example, women are often more 
likely to see their general practitioners on a regular basis16 
leading to a higher chance of recording of lifestyle variables 
such as BMI or smoking in women than in men.
We examined the presence of such variables in our data 
as follows:
•	 We fitted multivariable logistic regression models to 
identify predictors of missingness for each individual 
variable (one model for BMI missingness and a separate 
one for smoking missingness) using the whole dataset.
•	 We fitted logistic and linear regression models for binary 
variables (ie, current smoking status) and continuous 
variables (ie, BMI), respectively, to identify predictors 
of variable values based on the CCs dataset.
Automatic backward stepwise selection methods (with a 
p-exit<0.1 and p-entry<0.05) were used to identify key 
variables in all the above models. A number of variables, 
in addition to those included in the substantive model, were 
included for each database depending on the availability in 
the extracted analytical dataset as mentioned above. Table S1 
provides a list of variables that were examined as associated 
with missingness and the values of BMI or smoking data.
2. Specification of the imputation model
According to the MI guidelines,17 the MI model should 
include all variables planned for the substantive model; in our 
case, potential confounders, exposure and outcome (includ-
ing both VTE yes/no and the Nelson–Aalen estimate of the 
cumulative hazard rate function) as well as auxiliary variables 
that are associated with both missingness and variable values 
at the same time.17 The auxiliary variables may increase the 
likelihood of the MAR.3
3. Multiple imputation models
In this study, we applied MI using chained equations.18 A total 
of 15 datasets were imputed for each of the MI models. We 
evaluated different applications of MI where we used data 
recorded at different times in the databases: A) cross-sectional 
MI model (CSMI), including predictors detected exclusively 
using BMI and smoking data recorded in the year of therapy 
initiation; B) longitudinal MI model (MI−1y), including the 
variables in A and the value of BMI and smoking as recorded 
(when available) in the year before therapy initiation year; 
and C) longitudinal MI (MI±1y), including the predictors in 
A and B, but also the values of BMI and smoking as recorded 
(when available) in the year after therapy initiation year.
	 Stata statement:
	 mi impute chained (logit, omit(smoking predictors)) 
smoking (regress,omit(BMI predictors)) bmi= substan-
tive model and all predictors, add(number of imputations) 
rseed(random number)
	 mi impute chained (logit, omit(smoking predictors)) 
smoking smoking-1y smoking+1y (regress,omit(BMI 
predictors)) bmi bmi-1y bmi+1y = substantive model and 
all predictors without missing, add(number of imputa-
tions) rseed(random number)
4. Running the substantive model in the imputed datasets
The final step was fitting the proposed substantive model above 
to the imputed datasets. In our case, comparative risk of VTE 
across AOM status was estimated using Cox regression models.
	 Stata statement:
	 mi stset Time,failure(censoring==1) scale(365.25)
	 mi estimate:stcox i.exposure i.var1 i.var2 i.var3
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handling missing data in drug safety 
research
In addition to the three MI approaches, we also analyzed the 
data using CC analysis, in which patients without BMI and 
smoking status were excluded from the analysis.
In total, four strategies were compared, with CSMI 
being the reference standard. Baseline characteristics and 
incidence rates (IRs) of VTE in patients participating in CC 
compared with the whole study population were provided 
as an overall assessment of the potential bias underlying CC 
analysis. Then, differences in point estimates of each model 
compared to CSMI were calculated for each exposure cohort 
as  (HR
Alternative
−HR
CSMI
)/HR
CSMI
. Improvement in precision of 
each model (as a function of standard error [SE] size) rela-
tive to CSMI was finally estimated for all exposure cohorts 
as (SE
Alternative
−SE
CSMI
)/SE
CSMI
.
Patient involvement
No patient(s) or public representatives have been involved 
as part of this work.
Ethics and scientific committees’ approval
The study protocol was approved by the UK Independent 
Scientific Advisory Committee ISAC (REF 14_110R), CEIC 
Aragón (Number CP20/2014), and BIFAP Scientific Com-
mittee (Number 02_2015).
Results
The study populations were made up of 95,057 (BIFAP), 
12,688 (EpiChron), and 161,202 (CPRD) new users of AOM 
aged ≥50 years during 1998–2014. Among them, 422, 19, 
and 2,051 VTE cases during the first AOM treatment episode 
were detected, respectively, during a median time of follow-up 
between 1.04 and 1.71 years, depending on the EMR database.
Teriparatide in CPRD as well as denosumab and selec-
tive estrogen receptor modulator (SERM) in EpiChron were 
not assessed due to scarce numbers of exposed patients. No 
estimates were obtained in CC for denosumab in BIFAP and 
for teriparatide in EpiChron for the same reason.
Table 1 shows the availability of BMI and smoking data 
within up to 1 year before and after year of therapy initiation. 
Depending on the database, between 37.4% and 40.3% of new 
AOM users had BMI records, and between 55.8% and 90.7% 
had smoking records in the year of therapy initiation. Among 
those patients with information, mean BMI varied from 
28.65 (BIFAP) to 29.11 (EpiChron) kg/m2 and prevalence 
of current smokers ranged from 4.6% (EpiChron) to 23.1% 
(BIFAP). Among patients without information in the year of 
therapy initiation, few had BMI or smoking data recorded 
the year before (10.8% and 9.6% of total patients in BIFAP, 
7.7% and 1.7% in EpiChron, and 14.7% and 3.8% in CPRD, 
respectively). Even fewer additional patients had BMI and 
smoking records only the year after therapy initiation year 
(3.0% and 4.8% in BIFAP, 11.0% and 2.1% in EpiChron, 
and 8.5% and 1.5% in CPRD, respectively).
Table 2 shows the distribution of baseline characteristics 
in the whole study populations and in patients participating 
in the CC analysis, as well as the global IR of VTE dur-
ing the first treatment episode of AOM. Depending on the 
database, between 31% and 38% of new AOM users, that is 
32%–41% of total VTE cases, had complete records in the 
Table 1 Distribution of patients with BMI and smoking records by calendar year-blocks up to ±1 year from year of therapy initiation.
BIFAP,  
N=95,057
EpiChron Cohort, 
N=12,688
CPRD,  
N=161,202
BMI  
records
Smoking  
recordsa
BMI  
records
Smoking  
recordsa
BMI  
records
Smoking  
recordsa
N % N % N % N % N % N %
Available information 1 year before 36,608 38.50 52,277 55.00 3,974 31.32 8,937 70.44 59,260 36.76 144,602 89.70
Information only 1 year before (data 
lacking on year of therapy initiation)
10,283 10.80 9,117 9.59 970 7.65 219 1.73 23,740 14.73 6,085 3.77
Information on year of therapy 
initiation
38,307 40.30 53,017 55.77 4,745 37.40 9,084 71.6 63,283 39.26 146,276 90.74
Available information 1 year after 33,908 35.70 50,139 52.70 4,792 37.77 9,032 71.19 56,514 35.06 143,781 89.19
Information only 1 year after (data 
lacking on year of therapy initiation and 
1 year before)
2,844 2.99 4,538 4.77 1,401 11.04 270 2.13 13,649 8.47 2,410 1.50
Notes: aSmoking values after assumption of considering those patients with recorded status of exclusively never smoker at age ≥40 years as non-smokers. Text and values 
in bold refer to the year of interest to collect BMI and smoking values (year of therapy initiation) and when missing data were needed to impute.
Abbreviations: BIFAP, Base de datos para la Investigación Farmacoepidemiológica en Atención Primaria; BMI, body mass index; CPRD, Clinical Practice Research Datalink.
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year of therapy initiation in relation to the substantive model 
and could, therefore, be included for the CC analysis. CC 
yielded a nonsignificant higher IR of VTE than for the whole 
study population in BIFAP and CPRD, but lower in EpiChron. 
The distribution of AOM cohorts was slightly different in 
CC versus the whole study populations, that is, SERM was 
slightly underrepresented in CC in BIFAP and EpiChron, as 
was strontium in CPRD. Restricting to CC also impacted the 
distribution of potential confounders, such as gender and age. 
For example, in BIFAP, 18% of those with complete records 
were between 50 and 59 years while in those with missing 
data 32% were between 50 and 59 years.
Table S1 shows the variables associated with the missing-
ness and/or the values of BMI or smoking data in the three 
databases, as well as those finally included in the MI model.
In BIFAP, predictors of BMI values were the calendar 
year, alcohol abuse, most of the diseases assessed (including 
aneurysm, COPD, asthma, dementia, diabetes, heart failure, 
liver disease, rheumatoid arthritis, peptic ulcer, renal diseases, 
treated VTE [outcome], a history of VTE, recent fractures, 
vein insufficiency or phlebitis, peripheral arterial disease, 
and cancer), the AOM cohort (exposure of  interest), and the 
prescription of other antiosteoporotic drugs, calcium–vita-
min D, corticosteroid drugs, heparin, and HRT. Predictors of 
current smoking were the calendar year, alcohol abuse, COPD, 
diabetes, rheumatoid arthritis, and prescription of other anti-
osteoporotic drugs, calcium–vitamin D, and corticosteroid 
drugs. Age and sex predicted both BMI and smoking values.
In EpiChron, predictors of BMI values were the calendar 
year, asthma, dementia, diabetes, vein insufficiency or phle-
bitis, cancer, and the prescription of other antiosteoporotic 
drugs, calcium–vitamin D, corticosteroids, and heparin. 
Predictors of smoking values were alcohol abuse, COPD, 
diabetes, heart failure, and other antiosteoporotic drugs, 
age, and sex.
In CPRD, predictors of BMI and smoking status were the 
calendar year, the AOM cohort (exposure), a history of VTE, 
recent fractures, vein insufficiency or phlebitis, the use of 
calcium–vitamin D, corticosteroids, and anticoagulant drugs. 
Rheumatoid arthritis, treated VTE (outcome), and prescrip-
tion of heparins and HRT were also predictors of BMI value, 
whereas hypnotic drugs predicted smoking status.
Figure S1 shows the distribution of the BMI and current 
smoking values as recorded in the database and as imputed 
in the 15 datasets for the three databases.
Change in risk estimation
Table 3 reports the HR (and 95%CI) produced for each AOM 
versus alendronic acid in each method by database. The risk 
of VTE associated with other oral bisphosphonates, strontium 
ranelate, teriparatide, and denosumab versus alendronic acid 
obtained in the CSMI for CPRD and BIFAP was published 
Table 2 Global IR of VTE during first treatment episode of AOM, and the distribution of baseline characteristics in the whole study 
population and in patients participating in complete case analysis
BIFAP EpiChron Cohort CPRD
Complete case 
participants 
(N=29,609)
All eligible  
patients 
(N=95,057)
Complete case 
participants 
(N=4,516)
All eligible  
patients 
(N=12,688)
Complete case 
participants 
(N=60,923)
All eligible  
patients 
(N=161,202)
VTE cases, N 163 422 6 19 848 2,051
IR /100,000 person-years (95% 
CI)
245.61  
(210.66–286.37)
215.96  
(196.31–237.58)
113.34  
(50.92–252.29)
132.81  
(84.71–208.21)
533.55  
(498.82–570.70)
485.20  
(464.65–506.66)
N % N % N % N % N % N %
Exposure cohort
Alendronic acid 11,634 39.30 36,182 38.10 1,457 32.26 3,852 30.40 48,713 79.96 127,121 78.86
Other bisphosphonates 11,823 39.90 37,594 39.50 1,964 43.49 5,644 44.50 10,487 17.21 29,007 17.99
Strontium ranelate 2,507 8.50 7,978 8.40 558 12.36 1,495 11.80 551 0.90 1,993 1.24
SERM 3,165 10.70 11,723 12.30 331 7.33 1,127 8.90 1,150 1.89 3,045 1.89
Teriparatide 393 1.30 1,287 1.40 205 4.54 569 4.50 4 0.01 7 <0.01
Denosumab 87 0.30 293 0.30 1 0.02 1 0 18 0.03 29 0.02
Females 27,010 91.20 86,187 90.70 4,101 90.81 11,414 89.96 47,624 78.17 129,661 80.43
Age at year of therapy initiation
50–59 years 5,441 18.40 26,160 27.50 701 15.52 2,894 22.81 6,538 10.70 19,579 12.15
60–69 years 8,743 29.50 27,593 29.00 1,417 31.38 3,832 30.2 14,647 24.0 37,499 23.26
70–79 years 11,011 37.20 28,026 29.50 1,736 38.44 3,844 30.3 22,095 36.3 52,897 32.81
≥80 years 4,414 14.90 13,278 14.00 662 14.66 2,118 16.69 17,643 29.0 51,227 31.78
Abbreviations: AOM, antiosteoporotic medications; BIFAP, Base de datos para la Investigación Farmacoepidemiológica en Atención Primaria; CPRD, Clinical Practice 
Research Datalink; IR, incidence rates; SERM, selective estrogen receptor modulator; VTE, venous thromboembolism.
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in a previous article focused on the clinical interpretation 
of those HRs.7
Table 4 shows HR differences produced in each method 
relative to CSMI (prespecified reference group) for each 
exposure cohort and database. Negative percentages indicate 
underestimation in HR with the alternative method versus 
CSMI. Big differences were found when comparing CC versus 
CSMI, where the HR moved in both directions, from 100.00% 
underestimation (in BIFAP, EpiChron, and strontium in CPRD) 
to 40.31% overestimation (for all other AOM in CPRD).
Little difference was found when comparing the HR pro-
duced in longitudinal MI−1y and MI±1y versus CSMI. Esti-
mates were higher or lower depending on exposure cohorts. 
Differences ranged from −5.14% to 2.26% and the highest 
discrepancies were found in the smallest exposure cohorts 
(all EpiChron exposure cohorts and denosumab in BIFAP).
Statistical power/accuracy
Table 5 shows SE differences for each method relative to 
CSMI by AOM cohort and database. Positive percentages 
mean precision improvement with CSMI. Precision improved 
always in CSMI versus CC (up to 160.28%). Relatively low 
or no improvement in power (ie, SE size reduction) was 
observed when using longitudinal MI analysis compared 
with CSMI (range 0.02%–0.80%).
Table 3 HR (and 95% CI) of VTE associated with each AOM versus alendronic acid according to each method (CC, 
CSMI, MI−1y, and MI±1y) and database
Alendronic 
acid
Other oral 
bisphosphonates
Strontium  
ranelate
SERM Teriparatide Denosumab
BIFAP
Complete cases, N 11,634 11,823 2,507 3,165 393 87
HR (95% CI) Ref 0.85 (0.61–1.18) 0.81 (0.40–1.61) 0.80 (0.35–1.80) 0.45 (0.06–3.25) –
All eligible patients, N 36,182 37,594 7,978 11,723 1,287 293
HR CSMIa (95% CI) Ref 0.96 (0.78–1.18) 1.19 (0.82–1.74) 0.93 (0.58–1.50) 1.27 (0.59–2.71) 1.77 (0.25–12.66)
HR MI−1y (95% CI) Ref 0.96 (0.78–1.18) 1.19 (0.82–1.74) 0.93 (0.58–1.50) 1.26 (0.59–2.71) 1.78 (0.25–12.79)
HR MI±1y (95% CI) Ref 0.96 (0.78–1.18) 1.19 (0.82–1.74) 0.94 (0.58–1.50) 1.27 (0.59–2.71) 1.75 (0.24–12.51)
EpiChron Cohort
Complete cases, N 1,457 1,964 558 331 205 1
HR (95% CI) Ref 0.31 (0.03–3.52) – – – –
All eligible patients, N 3,852 5,644 1,495 1,127 569 1
HR CSMI (95% CI) Ref 0.88 (0.33–2.35) 0.38 (0.05–3.20) – 0.69 (0.08–5.81) –
HR MI−1y (95% CI) Ref 0.87 (0.32–2.33) 0.38 (0.05–3.26) – 0.65 (0.08–5.60) –
HR MI±1y (95% CI) Ref 0.87 (0.32–2.34) 0.39 (0.05–3.27) – 0.66 (0.08–5.69) –
CPRD
Complete cases, N 48,713 10,487 551 1,150 4 18
HR (95% CI) Ref 1.09 (0.92–1.30) 0.60 (0.28–1.26) 1.02 (0.46–2.30) – 4.84 (0.68–34.49)
All eligible patients, N 127,121 29,007 1,993 3,045 7 29
HR CSMIa (95% CI) Ref 1.05 (0.94–1.18) 0.90 (0.61–1.34) 0.82 (0.50–1.35) – 3.47 (0.49–24.65)
HR MI−1y (95% CI) Ref 1.05 (0.94–1.17) 0.89 (0.60–1.33) 0.82 (0.50–1.35) – 3.46 (0.49–24.62)
HR MI±1y (95% CI) Ref 1.05 (0.94–1.18) 0.90 (0.60–1.33) 0.83 (0.51–1.37) – 3.50 (0.49–24.88)
Notes: aHR (95% CI) of VTE associated with other oral bisphosphonates, strontium ranelate, teriparatide, and denosumab versus alendronic acid obtained in the CSMI for 
CPRD and BIFAP was published in a previous article focused on the clinical interpretation of those HRs.7 En dashes indicate that no estimates were obtained due to small 
cohort sizes.
Abbreviations: AOM, antiosteoporotic medications; BIFAP, Base de datos para la Investigación Farmacoepidemiológica en Atención Primaria; CC, complete case analysis; 
CPRD, Clinical Practice Research Datalink; CSMI, cross-sectional MI model; HR, hazard ratio; MI, multiple imputation; SERM, selective estrogen receptor modulator; VTE, 
venous thromboembolism.
Table 4 HR differences according to each method relative to 
CSMI for each exposure cohort and database
HR differences versus CSMI
Database AOM cohorta Complete  
case (%)
MI–1y  
(%)
MI±1y  
(%)
CPRD Other  
bisphosphonates
3.92
−0.29 −0.14
BIFAP
−11.57 −0.24 −0.07
EpiChron
−64.81 −1.40 −0.98
CPRD Strontium  
ranelate
−33.65 −0.84 −0.63
BIFAP
−32.50 −0.23 0.00
EpiChron
−100.00 1.01 2.26
CPRD SERM 24.58 0.25 1.32
BIFAP
−14.34 0.03 0.25
BIFAP Teriparatide
−64.57 −0.05 0.13
EpiChron
−100.00 −5.14 −3.74
CPRD Denosumab 40.31
−0.17 0.94
BIFAP b 1.02
−1.14
Notes: Percentages quantify the higher (positive %) or lower (negative %) HR 
obtained with respect to CSMI. aTeriparatide in CPRD as well as denosumab and 
SERM in EpiChron were not assessed due to small cohort sizes. bNo estimates were 
obtained due to small cohort sizes.
Abbreviations: AOM, antiosteoporotic medications; BIFAP, Base de datos para la 
Investigación Farmacoepidemiológica en Atención Primaria; CPRD, Clinical Practice 
Research Datalink; CSMI, cross-sectional MI model; HR, hazard ratio; MI, multiple 
imputation; SERM, selective estrogen receptor modulator.
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Discussion
Our purpose was to compare four methods used for handling 
BMI and smoking missing data as potential confounders in a 
clinical use case – a comparative drug safety study of the risk 
of VTE associated with different AOM. We compared results 
from CC analysis and MI based only on cross-sectional 
records (reference method as based on previous simulation 
studies), or after adding within-patient longitudinal records. 
The study was performed in three electronic primary care 
databases from the UK and Spain. Our findings can be sum-
marized as follows.
First, we observed that missing BMI and smoking values 
in the three databases were not completely at random since 
multiple predictors were associated with the values and 
missingness in the three databases. For example, in BIFAP, 
18% of those with complete records were between 50 and 59 
years while in those with missing data 32% were between 50 
and 59 years. Age was also associated with the values of BMI 
and smoking and, consequently, the risk of VTE associated 
with different AOM obtained in CC analysis is likely to be 
biased. Indeed, we found substantial differences in the risk 
estimates based on CC and CSMI. The sample sizes were 
also reduced in the CC analyses, which led to a significant 
power loss of up to 160%, compared with base-case CSMI.
Second, an extra level of imputation was added to CSMI, 
which took advantage of the information on BMI and 
 smoking values recorded 1 year apart (either before or after 
index year) as predictors. In our study, these longitudinal 
MI models did not improve precision substantially when 
compared with CSMI-based risk estimates.
The intermittent pattern of records completeness in EMR 
is common. Previous authors using measurements collected 
at different time points in MI strategies have failed to reveal 
the best-performing method, suggesting further research to 
compare different imputation methods.19,20 Some further strat-
egies used the data by time blocks and their temporal order-
ing.13,21,22 A further simulation study considering correlation 
over time suggested an optimal use of data available, the gain 
relative to baseline MI being dependent on the strength of the 
correlations among variables collected over time.13
A potential explanation for the lack of gain in precision 
in our study is that the large study cohorts provided enough 
cross-sectional information for predicting and imputing val-
ues to such an extent that records within 1 extra year were not 
as informative as expected. Also, few patients had values of 
BMI or smoking records 1 year apart, therefore, adding very 
little data to that available in the year of therapy initiation. 
Furthermore, a slight loss of precision was observed when 
adding longitudinal information to the analysis of study 
cohorts that were smallest in size and shortest in time con-
tribution. A possible reason for this could be the availability 
in the time of smoking data, which was used for assuming 
noncurrent smoking status whenever patients had consistent 
registries of noncurrent smoking throughout their life. This 
was previously done by other authors,13 entailing correlation 
within time blocks. This deterministic assumption was based 
on the fewer and therefore more uncertain records of smok-
ing status in the EpiChron database compared with the other 
databases covering longer periods and wider populations.
CSMI analysis preserves power using the whole study 
population while accounting for variance of imputed values 
(Rubin’s rule23). In the current study, BMI and smoking val-
ues reached realistic distributions in the three databases after 
imputation based on multiple predictors (Figure S1). Under 
those distributions and based on simulation studies,13 CSMI 
showed accurate risk estimates after adjusting by imputed BMI 
and smoking values based on multiple predictors of missing 
and observed values on the basic principle of replacement.4
We identified some practical challenges during the MI 
process, which are worth mentioning. First, we observed 
that the complexity of identification of potential variables 
to be included in the MI model increases with the increas-
ing number of variables to impute, especially when mutual 
adjustment for all variables with missing data is preferred.
Table 5 Standard error differences produced in each method 
relative to CSMI for each AOM cohort and database
Standard error differences 
versus CSMI
Database AOM cohorta Complete  
case (%)
MI–1y  
(%)
MI±1y  
(%)
CPRD Other  
bisphosphonates 
54.38
−0.09 −0.03
BIFAP 57.80 0.00
−0.07
EpiChron 147.31 0.52 0.43
CPRD Strontium  
ranelate
88.01
−0.09 −0.09
BIFAP 83.25
−0.01 −0.05
EpiChron 86.17 0.40
−0.13
CPRD SERM 63.12
−0.03 −0.01
BIFAP 72.13 0.00
−0.05
BIFAP Teriparatide 160.28
−0.04 −0.07
EpiChron b 0.79 0.80
CPRD Denosumab 0.05 0.02
−0.01
BIFAP b 0.00
−0.02
Notes: Positive percentages mean improvement with CSMI while negative 
percentages mean improvement with the alternative method. aTeriparatide in CPRD 
as well as denosumab and SERM in EpiChron were not assessed due to small cohort 
sizes. bNo standard errors were obtained due to small cohort sizes.
Abbreviations: AOM, antiosteoporotic medications; BIFAP, Base de datos para la 
Investigación Farmacoepidemiológica en Atención Primaria; CPRD, Clinical Practice 
Research Datalink; CSMI, cross-sectional MI model; MI, multiple imputation; SERM, 
selective estrogen receptor modulator.
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In the current study, two variables with missing data were 
imputed (ie, BMI and smoking) and mutually adjusted for 
each other in a way that we kept those value predictors that 
were significant in individuals who had complete records of 
both BMI and smoking, that is, predictors of BMI values 
were selected through a model adjusted by current smoking 
and, vice versa, predictors of current smoking were selected 
in a model adjusted by BMI values. However, eight different 
regression models for prediction examination were possible, 
where missingness and values of both variables acted as 
outcomes and potential predictors of each other. Still, an 
alternative would have been to select variables based on 
models without mutual adjustment for the other variable with 
missing data that probably simplifies the process.
Some limitations should be mentioned. First, the “MAR” 
distribution is an assumption that cannot be formally tested, 
and if not valid, the violation of such assumption would 
question the validity of CSMI as a “reference” method in 
our analysis. However, this is the challenge often faced by 
researchers in the field of drug safety research, where no 
reference risk estimate is available; in contrast, methodologi-
cal research using simulation studies13 has demonstrated the 
validity of CSMI. Finally, CSMI multivariable models sug-
gested that BMI and current smoking were actually weak 
confounders in the studied association between AOM and 
VTE. It is, therefore, plausible that the observed change in 
risk estimation observed in alternative (non-CSMI) methods 
might differ in other clinical scenarios where missingness 
affects stronger confounders; indeed, bigger differences 
among methods are expected when data are missing in strong 
confounders.
In summary, MI requires a preliminary evaluation of 
missing data and the patterns of observed values and predic-
tors. The complexity and time requirements increase with the 
number of variables with missing data to impute. If the initial 
explorative analyses of the missing data suggest that MAR 
is plausible and information is available within the dataset to 
account for MAR, then MI is recommended. However, among 
MI strategies, we observed a relatively small gain in precision 
when using longitudinal MI versus CSMI. Still, our model 
was based only on longitudinal data relatively close to the 
baseline (±1 year), but the simulation study of longitudinal 
MI by Welch et al13 demonstrated that for some variables 
with a strong correlation between values over time, the gain 
in precision can be substantial. In situations of small study 
cohorts or few cross-sectional predictors, we hypothesize 
that the inclusion of longitudinal records may be superior to 
using only cross-sectional records for MI, but further work 
is needed to evaluate this hypothesis. There may, however, 
be situations where it is impossible to perform MI as there 
may be insufficient data available to inform the MI model. 
In these cases, an option might be to exclude such an incom-
plete variable from the substantive model rather than exclude 
patients with missing data. Fortunately, MI is now supported 
by most common statistical software through fairly simple 
commands, despite being a relatively sophisticated method.
CC may result in biased estimates calculation when 
data are missing at random, which may be highly frequent 
in EMR, and our case study illustrates the superior benefits 
and applicability of CSMI compared with CC in a real-life 
drug safety study. In some cases, it may, however, be reason-
able to use CC analyses, such as when working with large 
datasets with few missing observations, because the risk of 
bias is minimal and the precision is still good. Likewise, if 
the missingness is not associated with the outcome, a CC 
analysis will provide unbiased estimates.24
In this study, we were able to demonstrate that the miss-
ing data were dependent on other observed variables. Hence, 
under the assumption that we have specified the imputation 
model correctly, the CSMI will provide unbiased estimates 
and, therefore, form the basis for the further analysis rather 
than the CC.
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Supplementary materials
Table S1 Association of the studied factors with the missingness and value of BMI and current smoking status in the three  databases, 
as well as those finally used for the multiple imputation of BMI and current smoking (grey columns)
BIFAP
BMI missing BMI value For BMI  
MI
Smoking missing Smoking 
value
For smoking 
MI
Adjusted by smoking value Adjusted by BMI value
Number of patients 53017 29609 38307 29608
Year of therapy initiation + + X + + X
Charlson index NA NA NA NA
Alcohol abuse – + X – + X
Aneurysm – + X – –
COPD – + X – + X
Asthma + + X – – X
Cerebrovascular disease – – – –
Dementia + + X – –
Diabetes + + X + + X
Hemiplegia + – – –
Heart failure – + X – –
HIV – – – –
Liver disease + + X + –
Rheumatoid arthritis – + X – + X
Myocardial infarction – – – –
Peptic ulcer – + X – –
Renal disease + + X – –
Other anti–osteoporotic medication – + X – + X
Calcium–Vitamin D – + X – + X
Corticosteroids + + X – + X
Hypnotic drugs NA NA NA NA
Heparin + + X + –
Oral anticoagulant drugs – – – –
Variables included in substantive model
Treated VTE (outcome) – + X – – X
AOM Cohort (exposure) – + X – – X
Sex + + X + + X
Age + + X + + X
History of VTE – + X – – X
Recent fractures + + X – – X
Vein insufficiency or phlebitis + + X – – X
Peripheral arterial disease – + X – – X
Cancer – + X – – X
Hormone replacement therapy (last year) + + X – – X
EpiChron Cohort
Number of patients 9083 4516 4564 8941
Year of therapy initiation – + X + – –
Charlson index NA NA NA NA
Alcohol abuse – – + + X
Aneurysm + – – –
COPD + – – + X
Asthma – + X – –
Cerebrovascular disease – – – –
Dementia + + X – –
Diabetes + + X – + X
Hemiplegia – – – –
Heart failure – – – + X
HIV – – – –
Liver disease + – – –
Rheumatoid arthritis – – – –
Myocardial infarction – – – –
(Continued)
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BMI missing BMI value For BMI MI Smoking missing Smoking 
value
For smoking 
MI
Adjusted by smoking value Adjusted by BMI value
Peptic ulcer – – – –
Renal disease – – – –
Other anti–osteoporotic medication – + X – + X
Calcium–Vitamin D – + X – –
Corticosteroids – + X – – –
Hypnotic drugs NA NA NA NA
Heparin – + X – – –
Oral anticoagulant drugs – – – –
Variables included in substantive model
Treated VTE (outcome) – – X – – X
AOM Cohort (exposure) – – X – – X
Sex – – X + + X
Age + + X + + X
History of VTE – – X – – X
Recent fractures – – X – – X
Vein insufficiency or phlebitis + + X – – X
Peripheral arterial disease – – X – – X
Cancer + + X – – X
Hormone replacement therapy (last year) + – X – – X
CPRD
Number of patients 84,847 49,598 63,283 49,592
Year of therapy initiation + + + +
Charlson index + + X + + X
Alcohol abuse NA NA NA NA
Aneurysm NA NA NA NA
COPD NA NA NA NA
Asthma NA NA NA NA
Cerebrovascular disease NA NA NA NA
Dementia NA NA NA NA
Diabetes NA NA NA NA
Hemiplegia NA NA NA NA
Heart failure NA NA NA NA
HIV NA NA NA NA
Liver disease NA NA NA NA
Rheumatoid arthritis + + X + – X
Myocardial infarction NA NA NA NA
Peptic ulcer NA NA NA NA
Renal disease NA NA NA NA
Other anti–osteoporotic medication – – – –
Calcium–Vitamin D – + X + + X
Corticosteroids + + X + + X
Hypnotic drugs + – X – + X
Heparin – – + +
Oral anticoagulant drugs + + X – + X
Variables included in substantive model
Treated VTE (outcome) + + X – – X
AOM Cohort (exposure) + + X – + X
Sex – + X + + X
Age + + X + + X
History of VTE + + X – + X
Recent fractures + + X – + X
Vein insufficiency or phlebitis + + X – + X
Peripheral arterial disease NA NA NA NA
Cancer NA NA NA NA
Hormone replacement therapy (last year) – + X – – X
Notes: NA since the Charlson comorbidity index was calculated (CPRD), or an equivalent list of comorbidities included in the latter index (EpiChron/BIFAP). Bold text 
highlights the variables finally included in the MI models.
Abbreviations: AOM, antiosteoporotic medications; BIFAP, Base de datos para la Investigación Farmacoepidemiológica en Atención Primaria; BMI, body mass index; 
CPRD, Clinical Practice Research Datalink; HIV, human immunodeficiency virus; MI, multiple imputation; NA, not applicable; VTE, venous thromboembolism.
Table S1 (Continued)
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Martín-Merino et al
Figure S1 Distribution of the BMI and current smoking values as recorded in the year of therapy initiation in the database (0), and as imputed in the 15 datasets (1–15) for 
the three databases from top to bottom (A) BIFAP, (B) EpiChron and (C) CPRD.
Abbreviations: BIFAP, Base de datos para la Investigación Farmacoepidemiológica en Atención Primaria; BMI, body mass index; CPRD, Clinical Practice Research Datalink.
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